Anti-thymocyte Globulin (Equine) API Manufacturers

compare suppliers & get competitive offers

Filters

Reset

Selected filters:

Type
Production region
Qualifications

 

 

 

To view suppliers for this material, you need to be logged in first.

 

 

 

 

 

This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.

 

 

Looking for Anti-thymocyte Globulin (Equine) API ?

Description:
Here you will find a list of producers, manufacturers and traders of Anti-thymocyte Globulin (Equine). You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Anti-thymocyte Globulin (Equine) 
Synonyms:
eATG , equine ATG  
Cas Number:
 
DrugBank number:
DB09312 
Unique Ingredient Identifier:
475247QF1Z

About Anti-thymocyte Globulin (Equine)

What makes Antilymphocyte immunoglobulin (horse) unique? Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that is then purified from the horse's serum to produce a usable drug product that can be used for immunosuppression. Although the exact mechanism of action is unknown, equine anti-thymocyte globulin targets a variety of immune system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and other cell types.

Equine ATG is currently indicated for the suppression of the immune system to prevent renal transplant rejection and in the treatment of aplastic anemia. Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for its therapeutic effect in these conditions. There are currently various ATG products available, which differ in the source of inoculated animal (rabbit, horse, or pig) and in the type of antigen product used to produce immunoglobulin (thymocytes, peripheral T cells, etc.).

Not sure if this is the exact product you're looking for? Contact the supplier by using the send inquiry button.